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Abstract
Background:  Central neurotensin (NT) administration results in a naloxone-insensitive
antinociceptive response in animal models of acute and persistent pain. Both NTS1 and NTS2
receptors were shown to be required for different aspects of NT-induced analgesia. We recently
demonstrated that NTS2 receptors were extensively associated with ascending nociceptive
pathways, both at the level of the dorsal root ganglia and of the spinal dorsal horn. Then, we found
that spinally administered NTS2-selective agonists induced dose-dependent antinociceptive
responses in the acute tail-flick test. In the present study, we therefore investigated whether
activation of spinal NTS2 receptors suppressed the persistent inflammatory pain symptoms
observed after intraplantar injection of formalin.
Results: We first demonstrated that spinally administered NT and NT69L agonists, which bind to
both NTS1 and NTS2 receptors, significantly reduced pain-evoked responses during the
inflammatory phase of the formalin test. Accordingly, pretreatment with the NTS2-selective
analogs JMV-431 and levocabastine was effective in inhibiting the aversive behaviors induced by
formalin. With resolution at the single-cell level, we also found that activation of spinal NTS2
receptors reduced formalin-induced c-fos expression in dorsal horn neurons. However, our results
also suggest that NTS2-selective agonists and NTS1/NTS2 mixed compounds differently modulated
the early (21–39 min) and late (40–60 min) tonic phase 2 and recruited endogenous pain inhibitory
mechanisms integrated at different levels of the central nervous system. Indeed, while non-selective
drugs suppressed pain-related behaviors activity in both part of phase 2, intrathecal injection of
NTS2-selective agonists was only efficient in reducing pain during the late phase 2. Furthermore,
assessment of the stereotypic pain behaviors of lifting, shaking, licking and biting to formalin also
revealed that unlike non-discriminative NTS1/NTS2 analogs reversing all nociceptive endpoint
behaviors, pure NTS2 agonists specifically inhibited paw lifting, supporting a role of NTS2 in spinal
modulation of persistent nociception.
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Conclusion:  The present study provides the first demonstration that activation of NTS2
receptors produces analgesia in the persistent inflammatory pain model of formalin. The dichotomy
between these two classes of compounds also indicates that both NTS1 and NTS2 receptors are
involved in tonic pain inhibition and implies that these two NT receptors modulate the pain-
induced behavioral responses by acting on distinct spinal and/or supraspinal neural circuits. In
conclusion, development of NT agonists targeting both NTS1 and NTS2 receptors could be useful
for chronic pain management.
Background
Endogenous neurotensin (NT) as well as centrally admin-
istered NT analogs produce dose-dependent analgesic
effects in either somatic or visceral pain paradigms [1].
Site-specific microinjections of NT also result in a mu-opi-
oid receptor-independent antinociceptive response in the
hot-plate and acetic acid-induced writhing tests in rodents
[2-6]. Molecular cloning and pharmacological data have
demonstrated the existence of at least three subtypes of
NT receptors referred to as NTS1, NTS2, and NTS3 [7-9].
However, there is now evidence that the analgesic action
of NT is mediated through activation of both G-protein
coupled receptors, NTS1 and NTS2 [1,10-12].
Originally, several studies pointed to the levocabastine-
sensitive low-affinity NTS2 subtype as a major NT antino-
ciceptor. The earliest indication was that the analgesic
effectiveness of a panel of metabolically stable peptide
and pseudopeptide analogs of NT did not correlate with
their binding affinities for NTS1 [13,14]. Among them,
intracerebroventricular (i.c.v.) or intrathecal (i.t.) injec-
tion of the NTS2-selective agonist, JMV-431, induced
strong antinociceptive responses in acute and visceral
pain tests in rodents [13,15]. Similarly, i.t. or intra-rostro-
ventromedial medulla (RVM) administration of both
selective NTS2 analogs, levocabastine and β-lactotensin
engendered analgesia in rats, as measured in the tail-flick
test [15-19]. Furthermore, i.c.v. administration of the NT
antagonist SR142948A, which recognizes both high- and
low-affinity NT sites, blocked NT-induced analgesia,
whereas the relative selective NTS1 antagonist SR48692
did not [14,20-22]. The contribution of NTS2 in regulat-
ing nociceptive processes was further demonstrated by
knockdown of the target protein by antisense approaches.
Indeed, sustained delivery of antisense oligodeoxynucle-
otides (ODN) directed against NTS2 to the brain, or spi-
nal administration of selective NTS2 dicer-substrate small
interfering RNA (siRNA), markedly reduced NT-induced
antinociception [13,19,23]. Accordingly, the generation
of NTS2-deficient mice confirmed the involvement of this
receptor in pain processing [24]. NTS2 receptors are also
well positioned to modulate nociception at several differ-
ent levels. Thus, in situ hybridization, autoradiographic
binding, and immunohistochemical studies have revealed
the presence of NTS2 receptors in cerebral regions impli-
cated in the descending control of nociceptive inputs such
as the periaqueductal gray (PAG), nuclei raphe magnus,
dorsalis, pallidus, and gigantocellular pars alpha [25-32].
Consistent with a role for NTS2 receptors in the mediation
of NT's spinal antinociceptive actions, high levels of NTS2
immunolabeling were observed within dorsal root gan-
glion cells and their central afferent terminals in the super-
ficial laminae of the dorsal horn, as well as in postsynaptic
elements throughout the dorsal horn of the rat spinal cord
[15].
NT also exerts its central analgesic effects by acting at
NTS1 sites. Intra-RVM injection of the selective-NTS1
receptor agonist PD149163 produces dose-dependent
thermal antinociception that is blocked by the NTS1
antagonist SR48692 [16,17]. Receptor knockout and
knockdown strategies support the pharmacological data.
Mice deficient in or lacking the NTS1 receptor fail to
exhibit NT-induced antinociception to thermal stimuli
[33,34]. The presence of high levels of NTS1 mRNA and
proteins in regions implicated in pain regulation such as
the RVM, PAG, lumbar dorsal root ganglion (DRG) and
spinal cord neurons also suggests the role of NTS1 in noci-
ceptive modulation [16,35-39]. Accordingly, we recently
demonstrated that i.t. NTS1 agonists significantly reverse
the formalin-induced nociceptive behaviors, providing
the first demonstration for a direct involvement of NTS1
receptors in NT-induced analgesia in a model of persistent
pain [37]. There is, however, substantial evidence that
receptors different from NTS1 also regulate nociceptive
signaling in a formalin tonic pain model. The involve-
ment of additional receptors is indeed suggested by the
finding that the reversal by SR48692 of the antinocicep-
tion produced by PD149163 was more complete than of
that induced by NT69L, a peptidase resistant NT analog
which binds to both NTS1 and NTS2 receptors with high
affinity, but in a non-selective manner [37].
The aim of the present study was, therefore, to evaluate
the potential implication of NTS2 receptors in persistent
pain. To test this possibility, antinociception produced by
spinal administration of selective NTS2 agonists was
assessed in rats receiving intraplantar formalin into the
right hind paw. Expression of the transcription factor c-fos
is used as a functional marker to identify the spinal neu-Molecular Pain 2009, 5:38 http://www.molecularpain.com/content/5/1/38
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rons that are activated by different forms of noxious stim-
ulation. We then investigated whether i.t. NTS2 agonists
suppressed formalin-evoked c-fos protein-like immunore-
activity in the rat lumbar spinal cord.
Materials and methods
Cell culture
The human embryonic kidney (HEK 293) cell line stably
expressing either rNTS1 or rNTS2 were cultured in 175
cm2 tissue culture flasks at 37°C in Dulbecco's modified
Eagle's medium (DMEM) with 2 mM L-glutamine. The
medium was supplemented with 5% fetal bovine serum,
0.1 mM nonessential amino acid, 1 U/ml penicillin and 1
mg/ml Geneticin (G418), in a humidified atmosphere of
95% air, 5% CO2. Cells were fed every 2 days with 20 ml
of medium. 70–80% confluent HEK 293 cells were
washed twice with phosphate-buffered saline solution,
scraped into 50 mM Tris-HCl (pH 7.4) buffer containing
1 mM EDTA and 250 mM sucrose and centrifuged at
15,000 g for 12 min at 4°C. Pellets were then re-sus-
pended in hypotonic TE buffer (50 mM Tris-HCl (pH 7.4)
buffer containing 1 mM EDTA) and membrane homoge-
nates were recovered by centrifugation for 30 min at 4°C.
The final protein concentration was determined with the
use of the BCA assay kit (Pierce Biotechnology Inc, Rock-
ford, IL).
Radioligand Binding Studies
For competition binding experiments, cell membranes
(20  μg per assay for rNTS1 and 100 μg per assay for
rNTS2) were incubated with 2 nM [3H]-NT for 45 min at
37°C in the binding buffer (50 mM Tris-HCl, pH 7.4, con-
taining 1 mM EDTA, 40 μg/ml bacitracin, and 1% bovine
serum album), in the presence of increasing concentra-
tions (from 10-11 to 10-5) of NT, NT69L (synthesized by E.
Richelson), levocabastine (kindly provided by Janssen
Research, Beerse, Belgium) and JMV-431 (synthesized by
J. Martinez). Binding was terminated by two successive
additions of 3 ml of ice-cold buffer and filtering under
vacuum through GF/B filters presoaked in binding buffer
containing 0.2% polyethyleneimine (48-well Brandel
Harvester). Filters were placed in scintillation vials con-
taining 5 ml scintillation liquid (Ecolite) and then
counted in a beta counter. Specific binding was calculated
as the difference between total binding (zero competing
compound) and nonspecific binding (excess competing
compound) and the IC50 values were determined from
inhibition curves as the unlabeled ligand concentration
inhibiting 50% of [3H]-NT-specific binding. Data were
analyzed by LIGAND [40] and represented as geometric
means, with the standard error of the geometric mean
being calculated as described in [41].
Animals, housing and habituation
Experiments were performed with adult male Sprague-
Dawley rats (250–300 g; Charles River, St-Constant, QC,
Canada) kept on a 12 h light/dark cycle and allowed ad
libitum access to food and water. Animals were individu-
ally acclimatized to Plexiglas enclosures for 3 consecutive
days prior to testing. The formalin test was always per-
formed by three different experimenters in a quiet room
and between 08.00 AM and 12.00 PM to reduce any vari-
ation related to circadian rhythm. The experimental pro-
cedures in this study were approved by the Animal Care
Committee of the University of Sherbrooke and were in
accordance with policies and directives of the Canadian
Council on Animal Care.
Behavioral studies
Intrathecal administration of NTS2 agonists before formalin injection
Behavioral experiments aimed at establishing the effects
of NT analogs and NTS2-selective agonists on formalin-
induced nocifensive behaviors. To this end, rats were
lightly anesthetized with isoflurane (Abbott Laboratories,
Montreal, QC, Canada) and injected intrathecally, at the
L5-L6 intervertebral space, with either NT (6 μg/kg),
NT69L (5 μg/kg), JMV-431 (5 to 60 μg/kg), or levocabas-
tine (0.5 and 5 μg/kg) diluted in 30 μl of physiological
saline (0.9% NaCl), 5 min before formalin administra-
tion. Control animals received physiological saline.
Formalin test
Antinociception was assessed using the formalin test as a
model of persistent pain. For this purpose, rats were
placed for a 60-min habituation period in the experimen-
tation room. Thereafter, rats received a 50 μl subcutane-
ous injection of diluted 2% formaldehyde (i.e. 5%
formalin, Fisher Scientific, Montreal, QC, Canada) into
the plantar surface of the right hind paw.
Following this, the rats were placed in clear plastic cham-
bers (30 × 30 × 30 cm) positioned over a mirror angled at
45°, in order to allow an unobstructed view of the paws,
and their behaviors were recorded for the next 60 min. An
intraplantar injection of formalin produced the biphasic
nociceptive response typical of this tonic pain model [42].
The two distinct phases of spontaneous pain behaviors
that occur in rats are proposed to reflect a direct effect of
formalin on sensory receptors (phase 1) and a longer last-
ing pain due to inflammation and central sensitization
(phase 2). Nocifensive behaviors were assessed using a
weighed score as described previously [43,44]. A nocicep-
tive mean score was determined for each 3 min period
during the recording time by measuring the amount of
time spent in each of four behavioral categories: 0, the
injected paw is comparable to the contralateral paw; 1, the
injected paw has little or no weight placed on it; 2, the
injected paw is elevated and is not in contact with any sur-Molecular Pain 2009, 5:38 http://www.molecularpain.com/content/5/1/38
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face; 3, the injected paw is licked, bitten, or shaken. The
weighted nociceptive score, ranging from 0 to 3, is calcu-
lated by multiplying the time spent in each category by its
assigned weight category, summing these products and
dividing by the total time for each 3 min block of time.
The total area under the curve (A.U.C.) for the inflamma-
tory phase (phase 2) was calculated between 21 to 60 min
for each animal. Phase 2 was further subdivided in early
(21–39 min) and late (40–60) phases and analyzed as
separate events [45]. Formalin-induced pain related
behavior may also be quantified by monitoring the
number and the duration of episodes of different behav-
ioral endpoints [46]. The cumulative time spent in both
lifting (state 2) and flinching/licking/biting (state 3),
reflecting behavioral reactions integrated at different CNS
levels, were also determined during the inflammatory
phase (21 to 60 min following formalin) [42].
Statistical analysis
Data are presented as means ± standard errors of the mean
(S.E.M.). All calculations and statistical analysis were per-
formed using Prism 4.0 and Instat 3.05 (Graph Pad Soft-
ware, San Diego, CA, USA). Nociceptive scores over the 3
min time blocks were analyzed using a two-way analysis
of variance for repeated measures, with comparisons
between experimental groups and the control group at
each time interval using Bonferroni's post hoc t-test. A one-
way ANOVA followed by Dunnett's post hoc t-test was used
to determine the significance of differences in the A.U.C.
and in the time spent in states 2 and 3. A difference in
responses between groups was considered significant with
P values; * P < 0.05 and ** P < 0.01.
c-fos immunohistochemistry
The immunohistochemical study was restricted to an
analysis of the effect of intrathecal pretreatment with
either 30 μg/kg of JMV-431, 5 μg/kg levocabastine, or
saline on the expression of c-fos-like immunoreactivity (c-
fos-LI) by intraplantar injection of 5% formalin into the
right hind paw. At 45 min following formalin injection,
rats were deeply anesthetized and perfused intraaortically
with ice-cold 4% paraformaldehyde (Fisher Scientific,
Montreal, QC, Canada) in 0.1 M PB, pH 7.4. The spinal
cord was isolated and then cryoprotected overnight at 4°C
in 30% sucrose in phosphate-buffered saline (PBS). Prior
to tissue sectioning, an incision was made in the ventral
horn of the contralateral side to allow spatial positioning
of the spinal cord for further analysis. Transverse frozen
sections (35-μm-thick) were then cut from the lumbar
segment (L4-L5) of the spinal cord with a sliding micro-
tome and processed by a free-floating slice immunohisto-
chemistry procedure. After elimination of endogenous
peroxidase activity with 0.3% hydrogen peroxide in PBS
for 1 h, the tissue sections were rinsed three times in PBS
and incubated for 1 h at RT in a blocking solution of 3%
normal goat serum (NGS) and 0.3% Triton X-100 in PBS.
After washing, free-floating sections were incubated over-
night at RT with the rabbit anti-c-fos polyclonal antibody
diluted 1:1000 in PBS (sc-52, Santa Cruz Biotechnology,
Santa Cruz, CA, USA), containing 1% NGS and 0.3% Tri-
ton X-100. The tissue was then washed three times in PBS
and transferred to a goat anti-rabbit biotinylated second-
ary IgG complex (1:200 in 1% NGS and 0.3% Triton X-
100 in PBS; Vector, Burlingame, CA, USA) for 1 h at RT
followed by exposing to avidin-biotin horseradish perox-
ydase complex (1:100; Vectastain ABC-Elite kit, Vector
Laboratories, Burlington, ON, Canada) for 1 h at RT. After
the final wash with PBS, the chromagen was developed
using nickel intensified 3,3'-diaminobenzidine (DAB,
0.01%) and 0.3% H2O2. Finally, the sections were thor-
oughly rinsed with PBS, mounted onto slides, dehydrated
in a series of graded alcohols, defatted in xylene, and
placed on coverslips.
Counting of c-fos protein immunoreactive nuclei
The greatest numbers of labeled neurons evoked by for-
malin were detected at the L4-L5 levels, corresponding to
segmental innervation of the rat plantar hind paw [47].
Sections were visually scanned and photographed using a
bright-field microscope (Leica DM4000B; Leica Microsys-
tems, Toronto, Canada). The individual sections were
printed and overlaid with an acetate sheet on which the
distribution of c-fos immunoreactive neurons was then
plotted. A neuron was considered to be labeled only if the
nucleus showed the characteristic staining of oxidized
DAB, and was distinct from background at magnifications
of 4×, 10×, and 20×. For the quantification of c-fos labeled
neurons, each section of the spinal cord was divided into
four regions of interest: the superficial laminae (laminae
I, IIo and IIi), the nucleus proprius (laminae III and IV),
the neck of the dorsal horn (laminae V and VI) and the
deep lamina X according to the cytoarchitectonic organi-
zation of the spinal cord [48]. The number of c-fos immu-
noreactive neurons in the four defined regions was
determined by averaging the counts made in 10–15 sec-
tions and expressed as mean ± S.E.M. of these values for
all the rats in that treatment group for statistical analysis
of the different experimental conditions. One-way analy-
sis of variance (ANOVA) was conducted using computer
software (Instat 3.05) for comparison across the experi-
mental conditions considering the number in each
defined region. A Dunnett's t-test was applied to assess
differences between the drug and vehicle groups. A value
of P < 0.05 was considered statistically significant.
Results
Competitive Binding Assays
Each NT analog was evaluated in competitive binding
assays against the two cloned rat NT receptors, with bind-
ing affinities defined as the concentration of peptideMolecular Pain 2009, 5:38 http://www.molecularpain.com/content/5/1/38
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required to inhibit 50% of the binding of [3H]-NT to
either NTS1 or NTS2 (IC50). The binding activity data in
Table 1 provide interesting information regarding the
selectivity of peptidase-resistant NT agonists for NTS2 ver-
sus NTS1. Thus, the metabolically stable NT(8–13) analog
JMV-431, protected at its N-terminus by a Boc group and
by a reduced pseudopeptide bond Y(CH2NH) in position
11–12 binds with 250 times greater affinity to rat NTS2
(IC50 = 19 ± 3 nM) than to rat NTS1 (IC50 = 4735 ± 100
nM). The non-peptide compound levocabastine (IC50 = 3
± 1 nM) was as potent as unlabeled NT (IC50 = 9 ± 2 nM)
in inhibiting [3H]-NT binding to HEK293 cell membranes
expressing NTS2. In addition, the NT(8–13) analog
NT69L, which contains a L-neo-tryptophan amino acid,
and exhibits high affinity for both rat (IC50 = 2.2 ± 0.5
nM) and human NTS1 [49] also appeared as a ligand with
a good affinity for the rat NTS2 (IC50 = 3.7 ± 0.4 nM).
Therefore, JMV-431 and levocabastine were used in the
behavioral experiments as selective ligands for NTS2,
whereas NT69L and NT were considered as agonists acting
on both NTS1 and NTS2 in a non-discriminative manner.
Intrathecal administration of NTS2 agonists reduces 
formalin-induced persistent spontaneous nociception
Intraplantar injection of formalin into the right hind paw
of saline-pretreated rats produced a typical biphasic spe-
cific nociceptive behavioral response consisting of an
acute phase (0–9 min) followed by a second prolonged
inflammatory phase (21–60 min) [37]. In the present
experiments, we examined the contribution of NTS2
receptors to the tonic late phase of the formalin response
by assessing the effects of different agonists of increasing
selectivity towards NTS2. Based on previous dose-
response and toxicity studies, we chose analgesic doses of
NT, NT69L, JMV-431 and levocabastine that were devoid
of non-specific motor effects [15,23,37].
Formalin-induced pain related behavior was first quanti-
fied by using the weighted scores method described by
Dubuisson and Dennis [44]. Injected intrathecally 5 min
before formalin, NT (6 μg/kg; n = 8) and NT69L (5 μg/kg;
n = 8), which bind to both NTS1 and NTS2 with a similar
affinity, significantly reduced pain-evoked responses dur-
ing the second phase of the formalin test (Fig. 1A). Specif-
ically, NT and NT69L pretreatment produced 48 ± 9% and
59 ± 13% reduction of pain behaviors in the tonic phase
compared to vehicle-treated rats, respectively (P < 0.05–
0.01, Fig. 2A). We then investigated whether spinally
administered selective-NTS2 receptor analogs exerted
antinociceptive effects following noxious chemical stimu-
lation. As shown in Fig. 1B, injection of different doses of
JMV-431 was significantly effective in inhibiting the aver-
sive behaviors induced by formalin. All doses tested mark-
edly attenuated the pain response to formalin during the
tonic phase, producing 24 ± 11% and 45 ± 18% of inhibi-
tion at 5 μg/kg and 30 μg/kg, respectively (n = 8; P < 0.05–
0.01, Fig. 2A). This reduction remained steady, however,
despite the use of higher doses of JMV-431 (45 ± 14% of
reduction in phase 2 at 60 μg/kg, n = 8; Fig. 1B). Finally,
signs of nociception evoked by formalin injection were
also reversed by i.t. levocabastine administration (0.5, 5
μg/kg), reaching 29 ± 5% of inhibition at the highest dose
(n = 6, P < 0.05; Figs. 1C, 2A).
Even if all compounds tested were able to inhibit spinal
nociceptive transmission induced by formalin injection,
differences in the profile of the inflammatory phase were
still observed between each drug. Indeed, the decrease in
the pain score of phase 2 determined for both JMV-431
and levocabastine was delayed in time when compared to
the NT69L profile (Fig. 1). Therefore, phase 2 was further
subdivided into an early phase (21–39 min) succeeding
the interphase and into a late one (40–60 min) corre-
sponding to the sustained inflammation plateau. For
comparative purposes, we evaluated the effects of equi-
analgesic doses of exogenous NT agonists in terms of inhi-
bition of phase 2 pain behaviors (Fig. 2). A statistically sig-
nificant decrease in the A.U.C. was noted for the non-
selective NTS1/NTS2 agonist, NT69L in both early and
late phases, with a maximal decrease of 70 ± 13% and
48% ± 19% respectively (P < 0.05–0.01; Fig. 2B). Interest-
ingly, the same analysis procedure applied to JMV-431
(30 μg/kg) and levocabastine (5 μg/kg) revealed that these
two selective NTS2 analogs exclusively reduced the behav-
ioral signs of formalin-induced pain by 48 ± 18% and 48
± 16% respectively in the late phase 2, while they had no
effect in the early phase (P < 0.05, Fig. 2B). These results
suggest that NTS1 and NTS2 agonists may act differently
Table 1: IC50 values (nM) for NTS1 and NTS2
Compound Structure rNTS1 rNTS2
Neurotensin pyroGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu-OH 5.0 ± 0.7 9.0 ± 2
NT69L N-methyl-Arg-Lys-Pro-L-neo-Trp-tert-Leu-Leu-OH 2.2 ± 0.5 3.7 ± 0.4
JMV-431 Boc-Arg-ArgPro-Tyrø(CH2NH)-Ile-Leu-OH 4735 ± 135 19 ± 3.2
Levocabastine non peptidic > 10,000 2.7 ± 1.3
Binding potencies of NT and related analogs were determined in competition experiments performed with HEK293 cells expressing either NTS1 
or NTS2. Data represent means ± SEM of at least three independent experiments carried out in triplicate.Molecular Pain 2009, 5:38 http://www.molecularpain.com/content/5/1/38
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Antinociceptive effects of acute injection of NT agonists on formalin induced pain behaviors Figure 1
Antinociceptive effects of acute injection of NT agonists on formalin induced pain behaviors. (a) Time course of 
analgesic effects of NT (6 μg/kg) and NT69L (5 μg/kg). Saline and drugs were intrathecally administered 5 min before the sub-
cutaneous injection of formalin. Nocifensive behaviors in male rats are expressed in 3 min intervals with a weighted pain score. 
(b, c) Pre-treatment with JMV-431 (5–60 μg/kg) or levocabastine (0.5–5 μg/kg) results in the inhibition of the persistent nox-
ious chemical stimulation. Each symbol represents the mean ± SEM of determinations made in six to eight animals.Molecular Pain 2009, 5:38 http://www.molecularpain.com/content/5/1/38
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to inhibit the nociceptive processing initiated by the per-
sistent noxious chemical stimulation.
Effects of intrathecal administration of NTS2 agonists on 
spinal and supraspinal behaviors induced by formalin
Pain-related behaviors elicited by formalin injection may
also be quantified by monitoring the duration of episodes
of different behavioral endpoints [46]. Such lifting, flinch-
ing, licking or biting specific behavioral responses are
integrated at different central nervous system levels upon
persistent nociception, involving the activity of spinal
and/or supraspinal nociceptive circuits [50-52]. By focus-
ing on the inflammatory phase, we then evaluated the
effects of i.t. pretreatment with NT agonists on the stereo-
typic behavior reactions to formalin (Fig. 3). At all doses
tested, both selective NTS2 agonists JMV-431 and levoca-
bastine markedly decreased the cumulative time spent in
lifting, reaching 71 ± 7% and 73 ± 5% of inhibition,
respectively (P < 0.05–0.01; Figs. 3A, B). In contrast to the
effects on lifting, none of the doses of either JMV-431 or
levocabastine had a significant effect on formalin-induced
flinching, licking and biting responses, pointing out the
role of NTS2 in spinal modulation of persistent nocicep-
tion (Figs. 3C, D).
Interestingly, the non-discriminative agonist NT69L had a
different action profile in reversing the spontaneous aver-
sive behaviors (Fig. 4). Thus, NT69L significantly reduced
by 74 ± 13% the lifting time elicited by formalin during
the tonic phase (P < 0.001; Fig. 4A). However, this peptide
was also effective in attenuating the flinching, licking and
biting responses (70 ± 15% maximum antagonism, P <
0.01; Fig. 4B), indicating that this NT analog affects both
spinally and supraspinally processed pain-related behav-
iors.
Effects of intrathecal pretreatment with NTS2 agonists on 
formalin-evoked c-fos-like immunoreactivity in spinal cord
The expression of the immediate early gene c-fos and of c-
fos protein in the spinal cord dorsal horn constitutes a
marker of neuronal activity that can be induced by nox-
ious stimuli [53]. Thus, c-fos immunohistochemistry was
performed on lumbar spinal dorsal horn sections to char-
acterize at the cellular level the relationship between the
pain-relieving effect of NTS2 agonists and the biochemical
changes of spinal nociceptive transmission (Figs. 5, 6). As
previously documented [47], tonic noxious chemical
stimulus produced by unilateral subcutaneous formalin
injection evokes c-fos expression in spinal cord neurons
(Fig. 5A). The pattern of nuclear c-fos-like immunoreactiv-
ity (c-fos-LI) was consistent with the known nociceptive
primary afferent input from the hindpaw. Indeed, dense
labeling was detected, at the L4-L5 segmental levels, prin-
cipally in neurons located in the superficial dorsal horn
(laminae I and IIo) and in the neck of the dorsal horn
Effects of NT compounds on the formalin-induced nocicep- tive behavioral responses manifested during the inflammatory  phase Figure 2
Effects of NT compounds on the formalin-induced 
nociceptive behavioral responses manifested during 
the inflammatory phase. (a) The antinociceptive 
response, expressed as mean area under the curve (A.U.C.), 
is measured during the second phase of the formalin test 
(21–60 min). Formalin-induced nociceptive behaviors are 
reduced by i.t. administration of levocabastine (5 μg/kg), JMV-
431 (30 μg/kg), and NT69L (5 μg/kg) in comparison to con-
trol rats receiving saline injection. (b) Dissociation of phase 2 
in early (21–39 min) and late (40–60 min) phases. JMV-431, 
levocabastine, and NT69L significantly suppressed the tonic 
pain response in the late phase, but only NT69L was able to 
induce analgesia in early phase. *P < 0.05 and ** P < 0.01 
when compared with the vehicle-treated group (ANOVA fol-
lowed by Dunnett's multiple comparison test). Data are rep-
resented as the average ± SEM.Molecular Pain 2009, 5:38 http://www.molecularpain.com/content/5/1/38
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(laminae V and VI). A scattered staining was also recorded
in the nucleus proprius (laminae III and IV), a region that
predominantly contains cells only responsive to innocu-
ous stimulation. As described previously [37,54], only few
labeled neurons were present in both sides of the spinal
cord of non-stimulated rats (i.e. without formalin injec-
tion; Fig. 6).
We then evaluated the ability of JMV-431 and levocabas-
tine to suppress formalin-induced c-fos  protein expres-
sion. Spinal administration of JMV-431 markedly
decreased formalin-evoked c-fos-LI in all laminae (Fig 5B).
At a dose of 30 μg/kg, injection of JMV-431 reduced the
number of c-fos-LI neurons in the ipsilateral laminae I-II,
laminae III-IV and laminae V-VI by 31 ± 7%, 36 ± 5% and
37 ± 5%, respectively (P < 0.001 compared with control
group; i.e rats receiving i.t. saline and formalin injection;
n = 4) (Fig 6A). Accordingly, treatment with the other
NTS2 agonist, levocabastine also reversed the activation of
medullary neurons after the formalin-induced inflamma-
tion (Fig. 5C). Quantitative analysis revealed that c-fos-LI
neurons in ipsilateral laminae I-II, laminae III-IV, laminae
V-VI and laminae X were reduced by 26 ± 7%, 60 ± 5%, 53
± 3% and 56 ± 8%, respectively, following administration
of levocabastine (5 μg/kg; P < 0.05 – 0.001 compared with
control group; n = 4) (Fig 6A). The non-selective agonist
NT69L also attenuated the spinal nociceptive neuronal
responses induced by formalin injection (not shown).
The number of c-fos-LI neurons evoked by formalin in the
superficial layers, the nucleus proprius, and the neck of
Effects of NTS2 selective agonists on stereotypic behavior reactions to formalin Figure 3
Effects of NTS2 selective agonists on stereotypic behavior reactions to formalin. The cumulative nociceptive 
response time of lifting, licking, shaking and biting the injected paw was measured during the second phase (21–60 min). Both 
NTS2 agonists JMV-431 (a, b) and levocabastine (c, d) significantly reduce phase 2 lifting but do not reverse formalin-evoked 
licking/shaking/biting behaviors. The vertical bars denote SEM. * P < 0.05 and ** P < 0.01 when compared with the saline-
treated group (ANOVA followed by Dunnett's multiple comparison test).Molecular Pain 2009, 5:38 http://www.molecularpain.com/content/5/1/38
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the dorsal horn of the ispilateral side was greater than that
in the contralateral area. Both NTS2 agonists were, how-
ever, efficient to bilaterally counteract formalin-induced
neuronal activation (Fig. 6B). The contralateral immuno-
reactivity of c-fos was reduced by pre-treatment with either
JMV-431 (laminae I-II (45 ± 7%), laminae III-IV (23 ±
4%) and laminae V-VI (42 ± 4%); P < 0.05 – 0.001 versus
control group; n = 3) or levocabastine (74 ± 7%, 72 ± 7%,
77 ± 5% and 98 ± 1% of reduction in laminae I-II, laminae
III-IV, laminae V-VI and lamina X, respectively; P < 0.001
versus control group; n = 3).
Discussion and conclusions
The majority of studies on pain processing have used, as a
behavioral model of pain, the withdrawal reflex threshold
of a limb provoked by a brief noxious stimulus, usually
thermal, mechanical, or electrical. Although such tradi-
tional nociceptive tests have considerably improved our
knowledge of pain mechanisms, the relevance of these
models for understanding activity in chronic pain states is
somehow limited. Indeed, pain associated with injury and
disease is long lasting and frequently associated with
inflammation and psychological distress. The molecular
and cellular changes observed in nociceptive modulatory
circuits provide evidence of this complex functional reor-
ganization occurring in the presence of persistent pain
[55,56]. Furthermore, there is a clear indication that sup-
pression of phasic and tonic pain can involve distinct
mechanisms [57,58]. In this regard, the formalin test was
developed as a model of tonic pain that has a greater rele-
vance to clinical pain than an acute phasic pain test
[42,46]. The local injection of formalin into the hindpaw
produces a characteristic biphasic behavioral response
[44,59]. The first phase of activity reflects a direct activa-
tion of sensory afferents and may thus be of limited value
in understanding mechanisms involved in persistent pain.
A particular focus of the present study was therefore on
the second phase, which corresponds to ongoing periph-
eral activity and involves central sensitization [42,43].
We have recently implicated NTS1 receptors in NT's anal-
gesic effects in tonic spinal pain paradigms [37]. However,
the experiments performed with the selective NTS1 antag-
onist SR48692 have suggested that another NT receptor
may participate to the regulation of pain signaling,
SR48692 partly reversing the analgesic effects of the non-
discriminative agonist NT69L. To our knowledge, the
present investigation demonstrates for the first time that
NTS2 agonists given intrathecally produce antinocicep-
tion in the formalin model of persistent inflammatory
pain (Fig. 1). These results are in agreement with previous
studies suggesting that NTS2 receptors play a role in the
regulation of spinal nociceptive inputs. Thus, administra-
tion of the selective NTS2 agonists, JMV-431 and levoca-
bastine, into the subarachnoid space of the lumbar spinal
region elicited analgesia in the tail-flick test [15,23]. The
dose effect seen here with levocabastine was previous
reported in different acute and tonic pain paradigms
[15,18]. The association of NTS2 receptors with different
sub-populations of DRG neurons and their presence
within the dorsal horn of the spinal cord also reinforced
the involvement of NTS2 receptors in the control of
incoming nociceptive messages. Indeed, NTS2 receptors
are expressed by substance P- and lectin B4-containing
Antinociceptive response to NT69L in the formalin tonic pain model Figure 4
Antinociceptive response to NT69L in the formalin tonic pain model. Intrathecal administration of the non-discrimi-
native NTS1-NTS2 agonist, NT69L significantly blocks phase 2 lifting (a) but also abolishes the other specific behavioral (b) 
observed during the inflammatory phase. Values represent means ± SEM. ** P < 0.01 and *** P < 0.001 when compared with 
the vehicle-treated group (ANOVA followed by Dunnett's multiple comparison test).Molecular Pain 2009, 5:38 http://www.molecularpain.com/content/5/1/38
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small ganglion cells as well as by large-sized NF200-posi-
tive neurons documented to carry primary nociceptive
sensory modalities and proprioceptive allodynia, respec-
tively [15]. A dense plexus of NTS2-immunoreactive neu-
ronal processes and numerous NTS2-expressing nerve cell
bodies were also detected in the superficial laminae of the
dorsal horn and in deeper layers III-V, suggesting that
NTS2 may play an important role in modulating the activ-
ity of spinal neurons [15].
Since the introduction of the formalin test, different
approaches have been used to assess formalin-induced
pain-related behaviors [42,50]. The initial behavioral
scoring in rats involved assigning of weighted scores to
different kind of behaviors, the intensity of each nocicep-
tive-related activity being directly correlated in proportion
to their category weights [43,44]. Based on the concept
that the different behavioral endpoints represent a one-
dimensional view of nociception, this method reflects the
overall pain experience of the animal being tested. Using
the weighted average pain scores, we found that NTS2-
selective agonists and non-discriminative compounds
gave rise to different action profiles during the inflamma-
tory phase of the formalin test. Indeed, both JMV-431 and
levocabastine had higher nociceptive scores than did
NT69L (which binds to both NTS1 and NTS2) during the
early phase 2 (21–39 min), while all drugs were efficient
in reducing pain during the late phase 2 (40–60 min) (Fig.
2). Accordingly, we recently demonstrated that the selec-
tive-NTS1 agonist, PD149163 behaved as NT69L, sup-
pressing pain-related behavioral activity in both early and
late parts of phase 2 [37]. The decrease in the analgesic
efficacy of NTS2-selective agonists observed during the
first half of phase 2 may be related to the non-involve-
ment of NTS2 during the early tonic inflammatory
responses. This hypothesis is supported by previous find-
ings showing that some receptors involved in the regula-
tion of pain processing differently modulate the early and
late tonic phases 2 [45,60]. For example, the synthetic opi-
oid analog, loperamide, only abolishes flinching behav-
iors in the second part of phase 2 [60]. Alternatively, it
may also reflect the active participation of NTS2 receptors
Figure 5
C-fos-like immunoreactivity at the L4-L5 spinal segment ipsi- lateral to the hindpaw injection of formalin in ipsilateral lum- bar sections of the dorsal horn of the spinal cord Figure 5
C-fos-like immunoreactivity at the L4-L5 spinal seg-
ment ipsilateral to the hindpaw injection of formalin 
in ipsilateral lumbar sections of the dorsal horn of the 
spinal cord. Three different situations are represented (all 
animals were injected with formalin): control rats that 
received saline (a) and rat receiving either JMV-431 (b) or 
levocabastine (c). Note that both JMV-431 and levocabastine 
reduced the level of formalin-evoked c-fos expression in the 
superficial dorsal horn. Scale bar: 200 μm.Molecular Pain 2009, 5:38 http://www.molecularpain.com/content/5/1/38
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during the interphase. We could indeed speculate that the
endogenous release of NT acting on NTS2 sites during the
interphase may reduce or mask the analgesic effects of
NTS2 agonists at the beginning of the inflammatory
phase. This delay in the antinociceptive effects of NTS2-
selective agonists possibly corresponds to the time frame
required for functional resensitization of NTS2 receptors.
This second hypothesis is reinforced by previous studies
showing that the interphase of the formalin test is the
result of active endogenous pain-inhibitory mechanisms
[61-67].
Aside from the weighted-scores technique, pain intensity
elicited by formalin injection may also be rated by the
assessment of each individual nociceptive behavior, such
as the total time the paw is kept elevated from the floor
[68,69], the number of times the rat flinches in a given
time period [57,59], or the time spent licking and biting
the injected paw [70]. A problem which may occur when
measuring only one behavior such as lifting is that if a
given treatment prevents this behavior, it is considered to
produce 100% analgesia, despite the possibility that the
rat may still exhibit other characteristic nociceptive behav-
iors, such as licking and biting [43]. However, the advan-
tage of single parameter recordings over the weighted-
scores method is that by taking into account the measure-
ment of multiple behaviors, it would be possible to assess
nociceptive behaviors in a manner that reflects the multi-
dimensional nature of pain experience [42,46,50,59].
Based on this method of analysis, we demonstrated that
NTS2-selective agonists behaved differently over the
inflammatory phase than non-discriminative compounds
and could therefore influence pain transmission in a dis-
tinctive manner. Thus, spinal delivery of JMV-431 and lev-
ocabastine significantly attenuated formalin-induced
lifting but not licking, biting and shaking responses dur-
ing the inflammatory phase (Fig. 3). Unlike NTS2 drugs,
the NT69L agonist, acting on both NTS1 and NTS2 recep-
tors, was able to reverse all nociceptive endpoint behav-
iors observed following tissue injury by intraplantar
formalin (Fig. 4). In Sprague-Dawley rats, these stereo-
typic behavioral reactions to formalin have been used
extensively to evaluate analgesic properties of drugs, and
different effects on lifting, shaking, licking, and biting
have also been observed with other agents [46,50]. Sys-
temic naloxone was indeed shown to increase formalin-
Regional analysis of the effects of NTS2 agonist administration on formalin-induced c-fos expression in spinal cord Figure 6
Regional analysis of the effects of NTS2 agonist administration on formalin-induced c-fos expression in spinal 
cord. Data represent the mean ± SEM of c-fos-positive neurons in the superficial laminae (laminae I-II), nucleus proprius (lami-
nae III-IV), neck of the dorsal horn (laminae V-VI), and lamina X of the L4-L5 segments, both ipsilateral (a) and contralateral 
(b) to formalin injection. Formalin increased c-fos expression in rats pretreated with saline compared to that for naïve rats. 
JMV-431 (30 μg/kg) and levocabastine (5 μg/kg) reduced the number of c-fos positive neurons in laminae I-II, III-IV and V-VI on 
the ipsilateral side. Both NTS2 agonists also reversed the spinal neuronal activity observed contralaterally. Statistical analysis 
between saline and agonist-treated groups: * P < 0.05 and ** P < 0.01; ANOVA followed by Dunnett's multiple comparison 
test.Molecular Pain 2009, 5:38 http://www.molecularpain.com/content/5/1/38
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induced flinching while simultaneously decreasing lick-
ing behavior [71]. Furthermore, peripheral injection of
NMDA receptor antagonists significantly attenuated for-
malin-induced lifting, while flinching behavior was not
affected [72]. This diversity of outcomes observed in the
formalin test was also reported with other spinally admin-
istered analgesics and antidepressants [73,74]. Even so,
concerns regarding motor effects influencing formalin
behaviors have been expressed. It has been advocated that
licking/biting behaviors are subjected to motor influences
and stereotypy, whereas flinching (e.g. paw elevations and
paw shakes) is a more spontaneous response, being less
influenced by other non-nociceptive behavioral changes
(e.g. motor) [42,46,59]. In this study, we focused on doses
that produced no observable motor impairment [75].
Consequently, it is unlikely that the suppression of lick-
ing/biting behaviors induced by medullary delivery of
non-selective NTS1/NTS2 compounds is related to altera-
tions in motor performance.
The differential effects of pure NTS2 agonists in eliciting
lifting and biting/licking responses noted here also sug-
gest that theses behaviors involve distinct mechanisms or
neural circuitry. Accordingly, pain-related behaviors can
be associated with distinct brain structures, including spi-
nal, brainstem, and cerebrally mediated responses to
nociceptive stimulation [76]. Well-known for evaluating
the effects of analgesic treatments on long-lasting pain,
the formalin test also allows the recording of behavioral
reactions relayed at different levels of the central nervous
system [50]. Aside from the spinal cord, formalin-evoked
responses seem to be mainly integrated in the brainstem
and midbrain, as decerebration and decortication do not
affect a range of behaviors [77,78]. Regarding the stereo-
typical nocifensive behaviors observed following forma-
lin administration, it was shown that the persistence of
limb flexion is largely a spinal reflex, as it can be evoked
following chronic spinalization [79]. Conversely,
supraspinal influences have been proposed to contribute
in licking/biting behavioral manifestations associated
with pain [74,80,81]. With this perspective, we could
therefore hypothesize that NTS2 agonists, reducing spon-
taneous pain manifested by paw lifting, may specifically
recruit spinal endogenous antinociceptive systems. Alter-
natively, the cumulative effects of NT69L (which binds to
both NTS1 and NTS2) on lifting and licking/biting behav-
iors may reveal that NTS1 receptor activation modulates
supraspinal nociceptive networks following formalin-
induced tissue injury.
Persistent nociceptive stimulation of primary sensory
afferents causes prolonged alterations in the neurochem-
istry and phenotype of postsynaptic dorsal horn neurons.
It enhances their excitability leading to hyperalgesia and
allodynia that develop after tissue injury. Accordingly,
noxious stimuli initiate specific spatio-temporal patterns
of c-fos expression within the spinal cord, allowing map-
ping of spinal nociresponsive neuronal populations
(including projection cells and both excitatory and inhib-
itory interneurons) [53,54]. In the present study, we used
c-fos expression as an anatomical correlate of the behavio-
ral measures to evaluate the antinociceptive activity of
NTS2 compounds. Our results revealed that intrathecal
NTS2 agonists reverse formalin-induced activation of c-
fos-like immunoreactivity within the dorsal horn (Figs. 5,
6). Specifically, we found that JMV-431 and levocabastine
significantly reduced c-fos-LI within the superficial layers
of the rat spinal cord (Rexed's laminae I-II), and also
exerted inhibitory effects on noxiously evoked c-fos
expression in deeper laminae. In view of its spinal distri-
bution [15], NTS2 receptor-mediated inhibition of nocic-
eptive transmission may occur at multiple laminae levels.
Converging evidence supports the idea that noxious
inputs to the spinal cord are actively modulated by
descending systems that serve not only to inhibit, but also
to facilitate nociception [52]. The participation of these
suprapinal sites is of great clinical significance as it is now
apparent that the development and maintenance of exag-
gerated pain states may result from an alteration of the
balance between facilitatory and inhibitory brain circuits
[82]. During the formalin response, the descending pain-
control influences originating from the rostroventrome-
dial medulla are indeed essential in maintaining the noci-
ceptive behavioral manifestations [52]. The mechanisms
by which NT receptor agonists induce analgesia may
therefore arise from local spinal pain inhibition or regula-
tion of supraspinal inputs. As spinal activation of NTS2
receptors was shown here to block specifically the nocice-
ptive behaviors integrated at the spinal cord level, we
might propose that spinal delivery of NTS2 agonists inter-
rupts conduction of the nociceptive processing by reduc-
ing excitability of peripheral primary afferent terminals
and inhibits dorsal horn c-fos nociresponsive interneuron
activity. However, since non-discriminative agonists
reversed supraspinal nocifensive behaviors, the antinocic-
eption observed could also rely on the inhibition of the
spino-bulbo-spinal loop by NTS1 receptor activation. It is
currently thought that this inhibitory drive is due to a
reduction in the activity levels of c-fos-positive neurons
projecting to upper brainstem structures [37].
To our knowledge, the present study is the first to demon-
strate that activation of NTS2 receptors induces analgesia
in a persistent pain model. The intrathecal administration
of NTS2 drugs was shown to reduce behavioral and
molecular markers of persistent inflammatory pain. Our
results also suggest that a dichotomy exists between the
spinal antinociceptive actions of NTS2-selective agonists
and NTS1/NTS2 mixed compounds. Further research toMolecular Pain 2009, 5:38 http://www.molecularpain.com/content/5/1/38
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design NTS1 and NTS2-selective novel analogs that cross
the blood-brain barrier may therefore offer new avenues
for the treatment of chronic pain.
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